Letairis

Product manufactured by Gilead Sciences, Inc

Application Nr Approved Date Route Status External Links
NDA022081 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Letairis Is Indicated For The Treatment Of Pulmonary Arterial Hypertension (Pah) (Who Group 1): To Improve Exercise Ability And Delay Clinical Worsening. In Combination With Tadalafil To Reduce The Risks Of Disease Progression And Hospitalization For Worsening Pah, And To Improve Exercise Ability [See Clinical Studies (14.2) ]. Studies Establishing Effectiveness Included Predominantly Patients With Who Functional Class Ii–iii Symptoms And Etiologies Of Idiopathic Or Heritable Pah (60%) Or Pah Associated With Connective Tissue Diseases (34%). Letairis Is An Endothelin Receptor Antagonist Indicated For The Treatment Of Pulmonary Arterial Hypertension (Pah) (Who Group 1): To Improve Exercise Ability And Delay Clinical Worsening. In Combination With Tadalafil To Reduce The Risks Of Disease Progression And Hospitalization For Worsening Pah, And To Improve Exercise Ability. Studies Establishing Effectiveness Included Trials Predominantly In Patients With Who Functional Class Ii–iii Symptoms And Etiologies Of Idiopathic Or Heritable Pah (60%) Or Pah Associated With Connective Tissue Diseases (34%) ( 1 ).

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Ambrisentan AMBRISENTAN ZINC538627

Comments